← All trials
NCT04635826
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2022
- Primary completion
- Jul 31, 2026
- Completion date
- Jul 31, 2027
- First posted
- Nov 19, 2020
- Last posted
- Nov 23, 2021
- Enrollment
- 100
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Alabama, BirminghamLead sponsor
- University of Alabama, BirminghamReponsible party - principal investigator
- University of Alabama, BirminghamOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.